title: Soft tissue sarcoma, version 2.2012: featured updates to the NCCN guidelines.
abstract: The major changes to the 2012 and 2011 NCCN Guidelines for Soft Tissue Sarcoma pertain to the management of patients with gastrointestinal stromal tumors (GISTs) and desmoid tumors (aggressive fibromatosis). Postoperative imatinib following complete resection for primary GIST with no preoperative imatinib is now included as a category 1 recommendation for patients with intermediate or high risk of recurrence. The panel also reaffirmed the recommendation for preoperative use of imatinib in patients with GISTs that are resectable with negative margins but associated with significant surgical morbidity. Observation was included as an option for patients with resectable desmoid tumors that are small and asymptomatic, not causing morbidity, pain, or functional limitation. Sorafenib is included as an option for systemic therapy for patients with desmoid tumors.
authors.affiliation: Fox Chase Cancer Center, USA.
authors.forename: Margaret
authors.initials: M
authors.lastname: von Mehren
authors.forename: Robert S
authors.initials: RS
authors.lastname: Benjamin
authors.forename: Marilyn M
authors.initials: MM
authors.lastname: Bui
authors.forename: Ephraim S
authors.initials: ES
authors.lastname: Casper
authors.forename: Ernest U
authors.initials: EU
authors.lastname: Conrad
authors.forename: Thomas F
authors.initials: TF
authors.lastname: DeLaney
authors.forename: Kristen N
authors.initials: KN
authors.lastname: Ganjoo
authors.forename: Suzanne
authors.initials: S
authors.lastname: George
authors.forename: Ricardo
authors.initials: R
authors.lastname: Gonzalez
authors.forename: Martin J
authors.initials: MJ
authors.lastname: Heslin
authors.forename: John M
authors.initials: JM
authors.lastname: Kane
authors.forename: Joel
authors.initials: J
authors.lastname: Mayerson
authors.forename: Sean V
authors.initials: SV
authors.lastname: McGarry
authors.forename: Christian
authors.initials: C
authors.lastname: Meyer
authors.forename: Richard J
authors.initials: RJ
authors.lastname: O'Donnell
authors.forename: Benjamin
authors.initials: B
authors.lastname: Paz
authors.forename: John D
authors.initials: JD
authors.lastname: Pfeifer
authors.forename: Raphael E
authors.initials: RE
authors.lastname: Pollock
authors.forename: R Lor
authors.initials: RL
authors.lastname: Randall
authors.forename: Richard F
authors.initials: RF
authors.lastname: Riedel
authors.forename: Scott
authors.initials: S
authors.lastname: Schuetze
authors.forename: Karen D
authors.initials: KD
authors.lastname: Schupak
authors.forename: Herbert S
authors.initials: HS
authors.lastname: Schwartz
authors.forename: Sridhar
authors.initials: S
authors.lastname: Shankar
authors.forename: Brian A
authors.initials: BA
authors.lastname: Van Tine
authors.forename: Jeffrey
authors.initials: J
authors.lastname: Wayne
authors.forename: Hema
authors.initials: H
authors.lastname: Sundar
authors.forename: Nicole R
authors.initials: NR
authors.lastname: McMillian
mesh_terms: D006801:Humans; D017410:Practice Guidelines as Topic / Q000592:standards*; D012509:Sarcoma / Q000175:diagnosis* / Q000628:therapy*